Applied Genetic Technologies Corporation has enrolled the first patient in the second cohort of a phase 1/2 trial of its adeno-associated virus-based gene therapy for X-linked retinitis pigmentosa, according to a press release.
The enrollment triggered a $10 million milestone payment under its collaboration agreement with Biogen, the release said.
The open-label, dose escalation trial is evaluating the safety and efficacy of subretinal administration of the therapy in patients with XLRP due to a mutation in the RPGR gene.
“We are pleased to announce this important milestone under our
Uncategorized